

Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: Slovakia, minimal size of the groups n = 5

EQA round: E12/21 - Hormones 1

Deadline: 04.05.2021

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of the participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U _{AV} = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]	Comparability					Traceability																
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	
(121) Total T3					1							1	1	100%									0
Samples and groups	[nmol/L]																						
Sample A		6,60			1							1	1	100%									0
Other					1	0						1											
Sample B		8,80			1							1	1	100%									0
Other					1	0						1											
(122) Total T4					1							1	0	0,00							1	0	0,00
Samples and groups	[nmol/L]																						
Sample A		96,0			1							1	0	0,00	CRV	132,8	1,4	17%	110	156	1	0	0,00
Other					1	0						1									1		
Sample B		0,000			1							1	0	0,00	CRV	100,6	1,0	17%	83,4	118	1	0	0,00
Other					1	1						1									1		
(123) TSH					22							22	21	95%									0
Samples and groups	[mU/L]																						
Sample A		25,4	2,2	8,8	22							22	22	100%									0
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		23,8	1,5	6,5	6	0	CVPG	24,4	0,29	14%	20,9	27,9									6		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		27,1	0,87	3,2	10	0	CVPG	27,4	0,085	14%	23,5	31,3									10		
Other					6	0						6											
Sample B		4,98	0,47	9,4	22							22	21	95%									0
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		4,64	0,23	5,0	6	0	CVPG	4,71	0,053	14%	4,05	5,37									6		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		5,30	0,15	2,9	10	0	CVPG	5,4	0,017	14%	4,64	6,16									10		
Other					6	1						6											
(124) Free T4					21							21	20	95%									0
Samples and groups	[pmol/L]																						
Sample A		22,6	2,8	12	21							21	20	95%									0
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		21,3	1,2	5,8	5	0	CVPG	20,4	0,25	13%	17,7	23,1									5		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		24,8	1,0	4,1	10	0	CVPG	24,4	0,11	13%	21,2	27,6									10		
Other					6	0						6											
Sample B		18,4	2,4	13	21							21	21	100%									0
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		16,2	1,6	10	5	0	CVPG	15,7	0,23	13%	13,6	17,8									5		

Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: Slovakia, minimal size of the groups n = 5

EQA round: E12/21 - Hormones 1

Deadline: 04.05.2021

Test	[unit]	Comparability										Traceability											
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	
Sample B		924	48	5,2	15							15	15	100%	CRV	857	12	30%	599	1120	15	15	100%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		929	33	3,5	6	0	CVPG	922	14	22%	719	1130											6
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		945	43	4,5	6	0	CVPG	917	5,2	22%	715	1120											6
Other					3	0																	3
																							2x 4/1, 1x 4/179
(303) Aldosterone	[nmol/L]				3																		3
Samples and groups																							3 3 100%
Sample A		0,948	0,10	11	3																		3
Other					3	0																	3
																							2x 1/218, 1x 2/66
Sample B		0,317	0,01	4,0	3																		3
Other					3	0																	3
																							2x 1/218, 1x 2/66
(304) Progesterone	[nmol/L]				15																		15
Samples and groups																							15 13 87%
Sample A		45,7	9,1	20	15																		15
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		40,1	2,8	7,0	5	0	CVPG	38,3	1,00	20%	30,6	46											5
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		55,4	2,9	5,2	6	0	CVPG	51,4	0,37	20%	41,1	61,7											6
Other					4	0																	4
																							2x 4/1, 2x 4/179
Sample B		7,91	0,95	12	15																		15
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		7,74	1,3	16	5	0	CVPG	7,04	0,26	20%	5,63	8,45											5
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		8,47	0,33	3,9	6	0	CVPG	8,03	0,085	20%	6,42	9,64											6
Other					4	0																	4
																							2x 4/1, 2x 4/179
(305) Testosterone	[nmol/L]				17																		17
Samples and groups																							17 16 94%
Sample A		14,4	1,5	10	17																		17
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		12,8	0,79	6,1	6	0	CVPG	12,6	0,22	22%	9,82	15,4											6
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		14,9	0,60	4,0	8	0	CVPG	14,9	0,088	22%	11,6	18,2											8
Other					3	0																	3
																							1x 4/1, 2x 4/179
Sample B		25,3	2,8	11	17																		17
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		22,8	1,3	5,6	6	0	CVPG	22,6	0,45	22%	17,6	27,6											6
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		26,8	1,5	5,6	8	0	CVPG	26,3	0,17	22%	20,5	32,1											8
Other					3	0																	3
																							1x 4/1, 2x 4/179
(306) 17-OH-progesterone	[nmol/L]				3																		3
Samples and groups																							2 2 100%
Sample A		8,95	1,4	16	3																		2
Other					3	0																	2
																							1x 1/999, 1x 2/66, 1x 4/183
Sample B		19,9	4,3	22	3																		2
																							2 2 100%
																							1x 1/999, 1x 2/66, 1x 4/183

